SG/CALL/BRISTOL-MYERS SQUIBB/75/0.1/17.01.25 | Delayed Deutsche Boerse AG 07:32:20 2024-06-10 am EDT | ||
| 0.004 EUR | 0.00% |
|
| Current month | +100.00% | ||
| 1 month | -33.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 0.004 | 0.00% |
| 24-06-07 | 0.004 | 0.00% |
| 24-06-06 | 0.004 | -20.00% |
| 24-06-05 | 0.005 | -37.50% |
| 24-06-04 | 0.008 | +166.67% |
Delayed Quote Deutsche Boerse AG
Last update June 10, 2024 at 07:32 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ86UF |
| ISIN | DE000SQ86UF9 |
| Date issued | 2023-02-16 |
| Strike | 75 $ |
| Maturity | 2025-01-17 (221 Days) |
| Parity | 10 : 1 |
| Emission price | 0.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.85 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.016 € |
| Spread % | 80.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48
USD
Average target price
53.19
USD
Spread / Average Target
+28.24%
- Stock Market
- Warrants
- Warrant
